1. Home
  2. TEX vs SYRE Comparison

TEX vs SYRE Comparison

Compare TEX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terex Corporation

TEX

Terex Corporation

HOLD

Current Price

$64.53

Market Cap

7.2B

Sector

Industrials

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$102.75

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TEX
SYRE
Founded
1933
2013
Country
United States
United States
Employees
10700
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.5B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
TEX
SYRE
Price
$64.53
$102.75
Analyst Decision
Buy
Strong Buy
Analyst Count
10
12
Target Price
$68.80
$85.08
AVG Volume (30 Days)
1.4M
1.7M
Earning Date
05-01-2026
05-08-2026
Dividend Yield
1.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,421,000,000.00
N/A
Revenue This Year
$47.67
N/A
Revenue Next Year
$6.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.73
N/A
52 Week Low
$41.70
$14.51
52 Week High
$74.69
$105.09

Technical Indicators

Market Signals
Indicator
TEX
SYRE
Relative Strength Index (RSI) 47.07 61.66
Support Level $58.54 $66.78
Resistance Level $66.33 $103.58
Average True Range (ATR) 3.05 6.10
MACD -0.68 0.09
Stochastic Oscillator 18.36 88.51

Price Performance

Historical Comparison
TEX
SYRE

About TEX Terex Corporation

Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: